InvestorsObserver
×
News Home

Is Achilles Therapeutics PLC (ACHL) a Smart Choice in Biotechnology Friday?

Friday, January 13, 2023 10:08 AM | InvestorsObserver Analysts

Mentioned in this article

Is Achilles Therapeutics PLC (ACHL) a Smart Choice in Biotechnology Friday?

Achilles Therapeutics PLC (ACHL) is near the bottom in its industry group according to InvestorsObserver. ACHL gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Achilles Therapeutics PLC gets a 25 rank in the Biotechnology industry. Biotechnology is number 20 out of 148 industries.

Overall Score - 38
ACHL has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on ACHL!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Achilles Therapeutics PLC Stock Today?

Achilles Therapeutics PLC (ACHL) stock is flat -0.44% while the S&P 500 has fallen -0.55% as of 9:50 AM on Friday, Jan 13. ACHL is unchanged $0.00 from the previous closing price of $1.14 on volume of 80,814 shares. Over the past year the S&P 500 is down -14.98% while ACHL has fallen -71.85%. ACHL lost -$1.68 per share the over the last 12 months. Click Here to get the full Stock Report for Achilles Therapeutics PLC stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App